首頁 > 市場調查報告書 > 醫療設備

醫學影像診斷癌症個人化醫學分子呈像/呈影劑核子醫學

全球放射性陶瓷市場，按放射性同位素（鎝99、鎵68、碘131、碘123、18F、Y-90、櫓-177、銅67、銅64等）按最終用戶/地區的應用: 競爭、預測、機會 (2027)

市場調查報告書

商品編碼

1131717

全球放射性陶瓷市場，按放射性同位素（鎝99、鎵68、碘131、碘123、18F、Y-90、櫓-177、銅67、銅64等）按最終用戶/地區的應用: 競爭、預測、機會 (2027)

Global Radiotheranostics Market By Radioisotope (Technetium-99, Gallium-68, Iodine-131, Iodine-123, 18F, Y-90, Lutetium 177, Copper 67, Copper 64, Others), By Application, By End User and By Region, Competition Forecast and Opportunities, 2027

出版日期: 2022年10月01日 | 出版商:

TechSci Research | 英文 118 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計全球放射治療市場在預測期內（2023-2027 年）將以驚人的複合年增長率增長。

放射治療是在成對的診斷成像和治療劑中使用放射性核素的過程。這是靶向診斷和治療的系統整合。癌症患病率的增加和具有抗腫瘤作用的可注射放射性藥物的日益普及對全球放射治療市場的增長做出了重大貢獻。此外，繼續支持研發以跟上當前放射治療藥物創新的勢頭，從而支持市場的增長。此外，由於我們成功地了解了癌症的潛在生物學以及改進了合成和設計靶向治療藥物的方法，放射治療藥物的臨床使用急劇增加。這對市場增長產生了積極影響。

在本報告中，我們分析了全球放射性陶瓷市場，包括整體市場規模、市場份額結構（按放射性同位素、按應用、按最終用戶）以及按地區和主要國家/地區的趨勢。我們正在調查詳細的市場趨勢、主要市場促進與製約因素、企業間市場競爭格局、主要企業概況、未來市場增長方向等。

內容

第一章產品概述

第二章分析方法

第 3 章執行摘要

第 4 章 COVID-19 對全球放射治療市場的影響

第 5 章客戶意見

對放射治療的認可
癌症患病率：按性別分類
癌症患病率：按年齡組
癌症患病率：按地區劃分
使用放射治療的好處

第6章臨床試驗分析

第七章專利分析

第 8 章。全球放射治療市場：未來展望

市場規模和預測
- 貨幣基礎
市場份額和預測
- 按放射性同位素（鎝99、鎵68、碘131、碘123、18F、Y-90、櫓 (Lu) 177、銅 (Cu) 67、銅 (Cu) 64、其他）
- 按用途（腫瘤與非腫瘤）
- 按最終用戶（醫院/診所、製藥/生物技術公司等）
- 按地區
- 按公司（2021 年）
產品市場地圖

第 9 章北美放射治療市場展望

市場規模和預測
市場份額和預測
北美：國家/地區分析
- 美國無線電陶瓷市場前景
- 墨西哥無線電陶瓷市場前景
- 加拿大無線電陶瓷市場前景

第 10 章歐洲放射治療市場展望

市場規模和預測
市場份額和預測
歐洲：國家/地區分析
- 法國無線電陶瓷市場展望
- 德國放射治療市場展望
- 英國無線電陶瓷市場前景
- 意大利無線電陶瓷市場前景
- 西班牙無線電陶瓷市場前景

第 11 章亞太放射治療市場展望

市場規模和預測
市場份額和預測
亞太地區：國家/地區分析
- 中國放射性陶瓷市場前景
- 印度放射治療市場展望
- 韓國無線電陶瓷市場展望
- 日本無線電陶瓷市場前景
- 澳大利亞放射治療市場展望

第 12 章南美放射治療市場展望

市場規模和預測
市場份額和預測
南美洲：國家/地區分析
- 巴西無線電陶瓷市場前景
- 阿根廷無線電陶瓷市場前景
- 哥倫比亞放射治療市場展望

第 13 章中東和非洲放射治療市場展望

市場規模和預測
市場份額和預測
中東和非洲：國家/地區分析
- 南非放射治療市場展望
- 沙特阿拉伯無線電陶瓷市場前景
- 阿拉伯聯合酋長國放射治療市場展望

第 14 章市場動態

驅動程序
任務

第 15 章市場趨勢和發展

第 16 章 SWOT 分析：全球放射治療市場

第 17 章競爭格局

TransCode Therapeutics, Inc.
Curium SAS
GE Healthcare Inc.
Bayer AG
Lantheus Medical Imaging, Inc.
Novartis AG
Spectrum Pharmaceuticals, Inc.
Ipsen S.A.
Actinium Pharmaceuticals, Inc. (ATNM)
Nordic Nanovector ASA
Y-mAbs Therapeutics, Inc.
Sofie Biosciences, Inc.
Terumo Corporation
Sirtex Medical Limited
Boston Scientific Corporation

第 18 章戰略建議

簡介目錄

Product Code: 11784

Global radiotheranostics market is anticipated to register growth at an impressive CAGR in the forecast period, 2023-2027. Radiotheranostics is a process that involves the use of radionuclides for paired imaging and therapy agents. It is a systematic integration of targeted diagnostics and therapeutics. The growing prevalence of cancer and the rising adoption of injectable radiopharmaceuticals that have antitumor effects are majorly contributing to the global radiotheranostics market growth. The increasing usage of radiotheranostics in cancer diagnosis and management is providing a thrust to the market. Radiotheranostics have enhanced therapy efficacy, the ability to manage adverse and critical health situations, which results in improved patient outcomes.

Moreover, the recent research and developments in the radiotheranostics field is creating a positive impact on the market growth. For instance, there have been major outcomes in radiotheranostics for prostate cancer and neuroendocrine tumors. Additionally, the regulatory approval of numerous radiotheranostics pairs is expected to boost their adoption for cancer treatments. For instance, the approvals of new radiotheranostics agents such as 177Lu-PSMA-617 and 177Lu-DOTATATE have resulted in the resurgence of research in the field of radiotheranostics and have proliferated the number of clinical trials and testing several other novel radiotheranostics. Furthermore, the continuous support in research and development to keep pace with current momentum in radiotheranostics innovations is supporting the market growth. Additionally, the clinical use of radiotheranostics agents have increased dramatically due to the successful strides that have been made in the understanding of underlying biology of cancer and enhanced methods for synthesizing and designing targeted theragnostic agents. This, in turn, is positively influencing the market growth.

Structural imaging is the most crucial component of staging, diagnosing, and assessing responses in cancer patients. However, patients and healthcare professionals are increasingly seeking non-invasive methods of investigating tumor phenotypes and assessing molecular and functional responses to therapy. Therefore, radiotheranostics, a combination of non-invasive diagnostic imaging with targeted therapy, is widely being implemented. As a result, the global market for radiotheranostics is anticipated to propel at a rapid pace in the coming years.

Market Segmentation

The global radiotheranostics market is segmented by radioisotope, application, end user, competitive landscape, and regional distribution. Based on the radioisotope, the market is differentiated between technetium-99, gallium-68, iodine-131, iodine-123, 18f, y-90, lutetium (lu) 177, copper (cu) 67, copper (cu) 64, and others. By offering the market is fragmented between oncology and non-oncology. The oncology segment is further bifurcated into thyroid cancer, neuroendocrine cancer, hepatocellular carcinoma, multiple myeloma and lymphoma, and other. The non-oncology application segment is further divided between joint infections, arthritis, bone pain, and others. On the basis of end user, the global market is segmented between hospitals & clinics, pharmaceutical & biotechnology companies, and others. The market analysis also studies the regional segmentation to devise regional market segmentation, divided among North America, Europe, Asia Pacific, Middle east and Africa, South America.

Company Profile

TransCode Therapeutics, Inc., Curium SAS, GE Healthcare Inc., Bayer AG, Lantheus Medical, Imaging, Inc., Novartis AG, Spectrum Pharmaceuticals, Inc., Ipsen S.A., Actinium Pharmaceuticals, Inc. (ATNM), Nordic Nanovector ASA, Y-mAbs Therapeutics, Inc., Sofie Biosciences, Inc., Terumo Corporation, Sirtex Medical Limited, and Boston Scientific Corporation are the leading market players responsible for the growth of global radiotheranostics market.

Report Scope:

In this report, global radiotheranostics market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Global Radiotheranostics Market, By Radioisotope:

Technetium-99
Gallium-68
Iodine-131
Iodine-123
18F
Y-90
Lutetium (Lu) 177
Copper (Cu) 67
Copper (Cu) 64
Others

Global Radiotheranostics Market, By Application:

Oncology
- Thyroid Cancer
- Neuroendocrine Cancer
- Hepatocellular Carcinoma
- Multiple Myeloma
- Lymphoma, Others

Non-Oncology
- Joint Infections
- Arthritis
- Bone Pain
- Others
- Global Radiotheranostics Market, By End User:

Hospitals & Clinics
Pharmaceutical & Biotechnology Companies
Others

Global Radiotheranostics Market, By Region:

North America
- United States
- Mexico
- Canada

Europe
- France
- Germany
- United Kingdom
- Italy
- Spain

Asia Pacific
- China
- India
- South Korea
- Japan
- Australia

Middle East and Africa
- South Africa
- Saudi Arabia
- UAE

South America
- Brazil
- Argentina
- Colombia

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global radiotheranostics market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Impact of COVID-19 on Global Radiotheranostics Market

5. Voice of Customer

5.1. Radiotheranostics Awareness
5.2. Cancer Prevalence, By Gender
5.3. Cancer Prevalence, By Age Group
5.4. Cancer Prevalence, Region
5.5. Benefits of Using Radiotheranostics

6. Clinical Trial Analysis

7. Patent Analysis

8. Global Radiotheranostics Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Radioisotope (Technetium-99, Gallium-68, Iodine-131, Iodine-123, 18F, Y-90, Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, Others)
- 8.2.2. By Application (Oncology v/s Non-Oncology)
  - 8.2.2.1. Oncology Applications (Thyroid Cancer, Neuroendocrine Cancer, Hepatocellular Carcinoma, Multiple Myeloma and Lymphoma, Others)
  - 8.2.2.2. Non-Oncology Applications (Joint Infections, Arthritis, Bone Pain, Others)
- 8.2.3. By End User (Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Others)
- 8.2.4. By Region
- 8.2.5. By Company (2021)
8.3. Product Market Map

9. North America Radiotheranostics Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Radioisotope (Technetium-99, Gallium-68, Iodine-131, Iodine-123, 18F, Y-90, Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, Others)
- 9.2.2. By Application (Oncology v/s Non-Oncology)
  - 9.2.2.1. Oncology Applications (Thyroid Cancer, Neuroendocrine Cancer, Hepatocellular Carcinoma, Multiple Myeloma and Lymphoma, Others)
  - 9.2.2.2. Non-Oncology Applications (Joint Infections, Arthritis, Bone Pain, Others)
- 9.2.3. By End User (Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Others)
- 9.2.4. By Country
9.3. North America: Country Analysis
- 9.3.1. United States Radiotheranostics Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Radioisotope
    - 9.3.1.2.2. By Application
    - 9.3.1.2.3. By End User
- 9.3.2. Mexico Radiotheranostics Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Radioisotope
    - 9.3.2.2.2. By Application
    - 9.3.2.2.3. By End User
- 9.3.3. Canada Radiotheranostics Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Radioisotope
    - 9.3.3.2.2. By Application
    - 9.3.3.2.3. By End User

10. Europe Radiotheranostics Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Radioisotope (Technetium-99, Gallium-68, Iodine-131, Iodine-123, 18F, Y-90, Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, Others)
- 10.2.2. By Application (Oncology v/s Non-Oncology)
  - 10.2.2.1. Oncology Applications (Thyroid Cancer, Neuroendocrine Cancer, Hepatocellular Carcinoma, Multiple Myeloma and Lymphoma, Others)
  - 10.2.2.2. Non-Oncology Applications (Joint Infections, Arthritis, Bone Pain, Others)
- 10.2.3. By End User (Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Others)
- 10.2.4. By Country
10.3. Europe: Country Analysis
- 10.3.1. France Radiotheranostics Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Radioisotope
    - 10.3.1.2.2. By Application
    - 10.3.1.2.3. By End User
- 10.3.2. Germany Radiotheranostics Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Radioisotope
    - 10.3.2.2.2. By Application
    - 10.3.2.2.3. By End User
- 10.3.3. United Kingdom Radiotheranostics Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Radioisotope
    - 10.3.3.2.2. By Application
    - 10.3.3.2.3. By End User
- 10.3.4. Italy Radiotheranostics Market Outlook
  - 10.3.4.1. Market Size & Forecast
    - 10.3.4.1.1. By Value
  - 10.3.4.2. Market Share & Forecast
    - 10.3.4.2.1. By Radioisotope
    - 10.3.4.2.2. By Application
    - 10.3.4.2.3. By End User
- 10.3.5. Spain Radiotheranostics Market Outlook
  - 10.3.5.1. Market Size & Forecast
    - 10.3.5.1.1. By Value
  - 10.3.5.2. Market Share & Forecast
    - 10.3.5.2.1. By Radioisotope
    - 10.3.5.2.2. By Application
    - 10.3.5.2.3. By End User

11. Asia-Pacific Radiotheranostics Market Outlook

11.1. Market Size & Forecast
- 11.1.1. By Value
11.2. Market Share & Forecast
- 11.2.1. By Radioisotope (Technetium-99, Gallium-68, Iodine-131, Iodine-123, 18F, Y-90, Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, Others)
- 11.2.2. By Application (Oncology v/s Non-Oncology)
  - 11.2.2.1. Oncology Applications (Thyroid Cancer, Neuroendocrine Cancer, Hepatocellular Carcinoma, Multiple Myeloma and Lymphoma, Others)
  - 11.2.2.2. Non-Oncology Applications (Joint Infections, Arthritis, Bone Pain, Others)
- 11.2.3. By End User (Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Others)
- 11.2.4. By Country
11.3. Asia-Pacific: Country Analysis
- 11.3.1. China Radiotheranostics Market Outlook
  - 11.3.1.1. Market Size & Forecast
    - 11.3.1.1.1. By Value
  - 11.3.1.2. Market Share & Forecast
    - 11.3.1.2.1. By Radioisotope
    - 11.3.1.2.2. By Application
    - 11.3.1.2.3. By End User
- 11.3.2. India Radiotheranostics Market Outlook
  - 11.3.2.1. Market Size & Forecast
    - 11.3.2.1.1. By Value
  - 11.3.2.2. Market Share & Forecast
    - 11.3.2.2.1. By Radioisotope
    - 11.3.2.2.2. By Application
    - 11.3.2.2.3. By End User
- 11.3.3. South Korea Radiotheranostics Market Outlook
  - 11.3.3.1. Market Size & Forecast
    - 11.3.3.1.1. By Value
  - 11.3.3.2. Market Share & Forecast
    - 11.3.3.2.1. By Radioisotope
    - 11.3.3.2.2. By Application
    - 11.3.3.2.3. By End User
- 11.3.4. Japan Radiotheranostics Market Outlook
  - 11.3.4.1. Market Size & Forecast
    - 11.3.4.1.1. By Value
  - 11.3.4.2. Market Share & Forecast
    - 11.3.4.2.1. By Radioisotope
    - 11.3.4.2.2. By Application
    - 11.3.4.2.3. By End User
- 11.3.5. Australia Radiotheranostics Market Outlook
  - 11.3.5.1. Market Size & Forecast
    - 11.3.5.1.1. By Value
  - 11.3.5.2. Market Share & Forecast
    - 11.3.5.2.1. By Radioisotope
    - 11.3.5.2.2. By Application
    - 11.3.5.2.3. By End User

12. South America Radiotheranostics Market Outlook

12.1. Market Size & Forecast
- 12.1.1. By Value
12.2. Market Share & Forecast
- 12.2.1. By Radioisotope (Technetium-99, Gallium-68, Iodine-131, Iodine-123, 18F, Y-90, Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, Others)
- 12.2.2. By Application (Oncology v/s Non-Oncology)
  - 12.2.2.1. Oncology Applications (Thyroid Cancer, Neuroendocrine Cancer, Hepatocellular Carcinoma, Multiple Myeloma and Lymphoma, Others)
  - 12.2.2.2. Non-Oncology Applications (Joint Infections, Arthritis, Bone Pain, Others)
- 12.2.3. By End User (Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Others)
- 12.2.4. By Country
12.3. South America: Country Analysis
- 12.3.1. Brazil Radiotheranostics Market Outlook
  - 12.3.1.1. Market Size & Forecast
    - 12.3.1.1.1. By Value
  - 12.3.1.2. Market Share & Forecast
    - 12.3.1.2.1. By Radioisotope
    - 12.3.1.2.2. By Application
    - 12.3.1.2.3. By End User
- 12.3.2. Argentina Radiotheranostics Market Outlook
  - 12.3.2.1. Market Size & Forecast
    - 12.3.2.1.1. By Value
  - 12.3.2.2. Market Share & Forecast
    - 12.3.2.2.1. By Radioisotope
    - 12.3.2.2.2. By Application
    - 12.3.2.2.3. By End User
- 12.3.3. Colombia Radiotheranostics Market Outlook
  - 12.3.3.1. Market Size & Forecast
    - 12.3.3.1.1. By Value
  - 12.3.3.2. Market Share & Forecast
    - 12.3.3.2.1. By Radioisotope
    - 12.3.3.2.2. By Application
    - 12.3.3.2.3. By End User

13. Middle East and Africa Radiotheranostics Market Outlook

13.1. Market Size & Forecast
- 13.1.1. By Value
13.2. Market Share & Forecast
- 13.2.1. By Radioisotope (Technetium-99, Gallium-68, Iodine-131, Iodine-123, 18F, Y-90, Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, Others)
- 13.2.2. By Application (Oncology v/s Non-Oncology)
  - 13.2.2.1. Oncology Applications (Thyroid Cancer, Neuroendocrine Cancer, Hepatocellular Carcinoma, Multiple Myeloma and Lymphoma, Others)
  - 13.2.2.2. Non-Oncology Applications (Joint Infections, Arthritis, Bone Pain, Others)
- 13.2.3. By End User (Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Others)
- 13.2.4. By Country
13.3. MEA: Country Analysis
- 13.3.1. South Africa Radiotheranostics Market Outlook
  - 13.3.1.1. Market Size & Forecast
    - 13.3.1.1.1. By Value
  - 13.3.1.2. Market Share & Forecast
    - 13.3.1.2.1. By Radioisotope
    - 13.3.1.2.2. By Application
    - 13.3.1.2.3. By End User
- 13.3.2. Saudi Arabia Radiotheranostics Market Outlook
  - 13.3.2.1. Market Size & Forecast
    - 13.3.2.1.1. By Value
  - 13.3.2.2. Market Share & Forecast
    - 13.3.2.2.1. By Radioisotope
    - 13.3.2.2.2. By Application
    - 13.3.2.2.3. By End User
- 13.3.3. UAE Radiotheranostics Market Outlook
  - 13.3.3.1. Market Size & Forecast
    - 13.3.3.1.1. By Value
  - 13.3.3.2. Market Share & Forecast
    - 13.3.3.2.1. By Radioisotope
    - 13.3.3.2.2. By Application
    - 13.3.3.2.3. By End User